Tamin Pharmaceutical Investment Company (TPICO) intends to purchase the required APIs and intermediate materials:

• Buparvaquone Injection Grade (2000 Kg)
• Florfenicol Injection Grade(10000 Kg) & Florfenicol Non- Injection Grade(15000 Kg)
• Ivermectin Injection Grade (1200 Kg)
• Tulathromycin Injection Grade (2000 Kg)
• Atorvastatin L1 (10000 Kg)
• Amikacin Sulfate Injection Grade (1000 Kg)

for its subsidiary companies through a public tender. Therefore, manufacturers and suppliers of the above items are requested to submit their price quotations in Euro, Yuan (CNY/RMB) , and Rupee (INR) currencies along with the conversion rates, the completed QF-2025 form, and the relevant certificate of analysis (COA), no later than 16:00 on Monday, October 13, 2025, to the following email address: Tenderholding@tpicopharma.com.

For more information, please contact: +98 21 2353 9111-Ext: 153.

Please kindly note the following points:

1. Strictly refrain from sending any copies to any email addresses other than the email mentioned above (including other email addresses of Tamin Pharmaceutical Investment Company and its subsidiaries).
2. The purchase will only be made from approved sources if the pricing is competitive. Tender participants are required to submit valid official documentation of their agency or sales authorization from the manufacturer along with their price offer to the above mentioned email address. Companies failing to adhere to this requirement will be refrained from price acceptance and participation in the tender.
3. The winner is required to issue a proforma invoice with a six-month validity, based on the buyer’s requested quantity while maintaining the quoted price
4. The winner must provide valid guarantees (as per announcement of credit evaluation committee of the subsidiaries) within a maximum of one week after the company’s request. (Failure to submit the required guarantees within the specified deadline will result in disqualification of the first winner and selection of another company as the tender winner. (
5. Any incompleteness or failure to accurately complete the QF-2025 form (attached) will result in the disqualification of the tender participant from the current tender.
6. The shipped consignments must have at least two-thirds of their shelf life remaining at the time of arrival at Iran’s customs and must fully comply with all GMP requirements and the physico-chemical specifications of the purchasing company and Food and Drug Administration of Iran (IFDA).
7. Companies failing to comply with the above requirements will be excluded from both the acceptance of the price and participation in the tender and if the winner company fails to meet their obligations, the winner will be prohibited from participating in future tenders of Tamin Pharmaceutical Investment Company (TPICO) and its subsidiaries.
8. Tamin Pharmaceutical Investment Company (TPICO) Holding and its subsidiaries are authorized to accept or reject the quoted prices and conduct the tender.

QUATATION FORM  = quo-form -2025